X4 Pharmaceuticals, Inc. (XFOR)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 3 | 0 | 0 | 0 | 3 | 35 | 16 | 16 |
| Operating profit | $m | -87 | -88 | ||||||
| Net profit | $m | -62 | -89 | -94 | -101 | -37 | -79 | -90 | - |
| EPS reported | $ | -1.87 | -1.20 | ||||||
| Operating cashflow per share | $ | -2.02 | -0.66 | ||||||
| Capex per share | $ | 0.07 | 0.00 | ||||||
| FCF per share | $ | -2.10 | -0.66 | ||||||
| Free cash flow | $m | -89 | -84 | ||||||
| Net debt | $m | -177 | -131 | ||||||
| Book value equity | $m | 186 | 155 | ||||||
| Book value per share | $ | 4.40 | 1.23 | ||||||
| Number of shares | m | 42.29 | 126.34 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 0.91 | 1.09 | ||||||
| P/S LTM | x | 4.82 | 10.68 | ||||||
| P/FCF LTM | x | -1.91 | -2.02 | ||||||
| EV/EBITDA LTM | x | -0.43 | -0.37 | ||||||
| EV/Sales LTM | x | 0.84 | 13.34 | ||||||
| Earnings Yield LTM | % | -46.82% | -16.57% | ||||||
| FCF Yield | % | -52.38% | -49.50% | ||||||
| Quality | |||||||||
| ROE | % | -42.51% | -63.05% | ||||||
| ROIC | % | -32.70% | -37.60% | ||||||
| Operating margin | % | -2.47% | -5.55% | ||||||
| Gross margin | % | +82.18% | +81.22% | ||||||
| FCF/Sales | % | -252.38% | -528.40% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +1273.2% | +519.75% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -1.15 | -1.08 | ||||||
| Net Debt/EBITDA | x | 2.03 | 2.45 | ||||||
| EBIT/Net interest | x | -9.79 | -10.06 | ||||||
| Net debt/market cap | % | +45.10% | +18.90% | ||||||
| Net debt/Equity | x | -0.95 | -0.84 | ||||||
| Gross debt/equity | x | 0.41 | 0.50 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free